{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-011104","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.278611+00:00","generated_at":"2026-05-16T10:41:51.694637+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kymera reports $1.6B cash; KT-621 Phase 2b AD data by mid-2027, asthma data late-2027","bullets":["Preliminary cash, cash equivalents and marketable securities of $1.6B as of Dec 31, 2025; runway into 2029.","KT-621 Phase 2b BROADEN2 trial in AD enrolling, data expected by mid-2027; BREADTH Phase 2b asthma trial initiated, data late-2027.","KT-579 Phase 1 healthy volunteer trial expected to start 1Q26 with data in 2H26; IRF5 degrader for lupus, RA.","At least one new first-in-class oral immunology development candidate to advance towards IND in 2026.","Partnered programs: KT-485/SAR447971 (IRAK4) with Sanofi Phase 1 expected in 2026; CDK2 program with Gilead ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-011104","json":"https://secwatch.observer/filing/0001193125-26-011104.json","markdown":"https://secwatch.observer/filing/0001193125-26-011104.md","text":"https://secwatch.observer/filing/0001193125-26-011104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526011104/0001193125-26-011104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526011104/d78447d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:41:51.694637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}